The EPS projection of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) for quarter ended 2016-08-31 is $-0.21. A week before, the EPS forecast was $-0.21 against target of $-0.21, a month earlier. This estimate stood at $-0.21 60 days earlier versus forecast of $-0.21 90 days earlier, confirming a deviation of 0%.
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) reported that 18 days ago, the positive EPS revisions were 0 and negative revisions at 0.
In last week, the per-share earnings was lowered 0 times and 0 times positively. In last 120, 60, 30 and 90 days the positive revisions were 2, 0, 0 and 2, respectively.
The downgrade of EPS estimates for Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) in the preceding 120, 60, 30 and 90 days were 0, 0, 0 and 0, in that order.
As per the latest update, for the quarter closed 2, the EPS estimate of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) was $-0.21. This projection was computed after accounting 4 calls. As reported on 2016-04-06 the EPS was $-0.14. The change was $0.05, demonstrating a percentage deviation of 26.32%. The projections confirmed a standard deviation of 0.03.
Quarterly Sales Estimates
For the fiscal 2016, the yearly sales target for Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) stands at $4.1 and the median estimate at $4.1. Almost 2 analysts announced their estimates.
The highest estimate is $8 while the lowest target is $0.2 showing standard deviation of 5.515%.
As many as 2 analysts released sales estimates reised in upside while 2 reduced sales estimates, demonstrating a deviation of 0%.
In last month, 2 revised sales number projection on upside while 2 lowered the sales target, demonstrating a deviation of 0%.
A quarter ago, 2 hiked sales estimations and 2 reduced sales forecast. Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) stated that the change in forecast was 0%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...